SEQUORA’s 10 mg MOTS-c contains a synthetic version of a naturally occurring mitochondrial peptide studied for its role in cellular energy use, glucose metabolism and AMPK signalling. Research also explores its relevance to age-related metabolic changes in men and women, including changes associated with menopause.
Already have an account? Log in
SEQUORA’s MOTS-c 10mg contains a synthetic version of a mitochondrial-derived peptide studied for its role in cellular energy regulation, glucose metabolism and responses to metabolic stress. Early research has explored its effects on insulin sensitivity and physical performance. MOTS-c has been investigated for its benefits for women in perimenopause or postmenopause who are going through metabolic shifts, weight gain and changing energy levels without clear explanation.
The 10mg figure indicates the total stated content, not the concentration or amount delivered per withdrawal. Review the specifications for your selected format.
All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.
MOTS-c is a peptide produced by the mitochondria, the parts of your cells that help generate energy. Researchers are studying its role in insulin sensitivity and how the body uses glucose. There’s also interest in its relevance during perimenopause and after menopause, when falling oestrogen can affect metabolism.
Yes. MOTS-c occurs naturally in both men and women. Research explores metabolic health, muscle function and age-related changes, making it relevant beyond women’s health.
Studies have reported improvements in metabolic function and physical performance, meaning MOTS-c has been found in certain environments to help with weight management and exercise.
In studies, metabolic improvements were observed over weeks to months, not days. Given that the underlying conditions MOTS-c targets: insulin resistance, metabolic aging, develop over years, it’s reasonable to expect meaningful assessment would require at least 8-12 weeks of use alongside objective metabolic monitoring, such as HbA1c, fasting insulin, and continuous glucose data.
Product information, handling and safety
What Temperature should I store my MOTS-c at?
What are the best practices for using MOTS-c safely?
The documentation behind MOTS-c and it's uses
SEQUORA’s 10 mg MOTS-c contains a synthetic version of a naturally occurring mitochondrial peptide studied for its role in cellular energy use, glucose metabolism and AMPK signalling. Research also explores its relevance to age-related metabolic changes in men and women, including changes associated with menopause.
Upon delivery store in a refridgerator between 2-8°C.
Avoid dropping or heavy-handling of your MOTS-c.
Please do not freeze your SEQUORA MOTS-c Pen as this can compromise the peptide.
Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.
Your SEQUORA MOTS-c Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.
SEQUORA MOTS-c Vials before reconstitution can last up to 4 years at -5°C
MOTS-c can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.
Before handling your MOTS-c, needles or injection material, ensure your research area is clean and clear.
Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.
If at any point the cleanliness of your injection or environment is compromised, restart this step.
Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.
Before using your SEQUORA MOTS-c Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.
If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.
Ensure that your needle tips, syringes and vials are safely disposed of post-use.
This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.
Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.
MOTS-c is an investigational peptide with a favourable and optimistic safety profile in published research data. It is a peptide thats natural form circulates in human blood and Phase 1 Data and clinical experiments report no serious adverse avents on doses up to 10mg per injection.
Injection-site reactions
These reactions may relate to the preparation, its ingredients or injection technique. Persistent or worsening symptoms should not be dismissed as a normal adjustment period.
Fatigue and headache
Fatigue and headache are described in some informal accounts and promotional summaries, but their frequency, cause and expected duration have not been established through adequate human trials of MOTS-c.
There is insufficient evidence to explain these symptoms as a harmless shift in energy metabolism or AMPK activation.
Other reported symptoms
Safety information about online MOTS-c use also describes palpitations, increased heart rate, sleep disturbance, fever and immune-type reactions. These reports are not verified clinical adverse-effect rates and cannot establish causation.
Blood glucose precautions
Preclinical research suggests effects on glucose metabolism. Whether injected MOTS-c causes clinically important low blood glucose in humans is uncertain. People using insulin or other medicines that can cause hypoglycaemia require particular caution and medical assessment.
Pregnancy and breastfeeding
Avoid use during pregnancy or breastfeeding because adequate safety information is unavailable.
When to seek medical help
Seek prompt assessment for persistent headache, marked fatigue, palpitations, fever or increasing injection-site redness, warmth, swelling or pain.
Call 999 immediately for difficulty breathing, sudden swelling of the lips, tongue or throat, chest pain, collapse or seizures.
About this information
The absence of documented harm in limited research does not establish the absence of liver, kidney, cardiovascular or other risks. This summary does not establish the safety, quality or suitability of a SEQUORA product for human use and does not replace medical advice.
The measures below address symptoms and preparation uncertainties in MOTS-c.
Injection-site irritation or bruising
Fatigue or headache
Palpitations or disturbed sleep
Stop use and seek medical advice for a new racing or irregular heartbeat or significant sleep disturbance. Avoid adding stimulant pre-workouts or additional research compounds while symptoms are assessed.
Call 999 for palpitations accompanied by chest pain, breathlessness or fainting.
Blood glucose precautions
Pregnancy and breastfeeding
Avoid use during pregnancy or breastfeeding. If exposure has occurred, seek individual medical advice rather than assuming harm has occurred.
About this information
There is no established safe dose or proven strategy for preventing MOTS-c reactions. Clinical supervision and pharmacy supply do not, by themselves, establish regulatory approval or eliminate uncertainties about an unapproved preparation.
Calculation basis: 10 mg total compound in a final solution volume of 1 ml, giving a concentration of 10 mg/ml. Each pen dial unit is assumed to deliver 0.01 ml, containing 0.1 mg.
| DOSE | SCHEDULE | PEN DIAL SETTING | WEEKLY TOTAL |
|---|---|---|---|
| 5 mg per injection | Once weekly | 50 | 5 mg |
| 2.5 mg per injection | Mon / Thu | 25 per injection | 5 mg |
Understanding the figures
The 10 mg figure represents the total stated compound content, not an individual dose. At a final volume of 1 ml, each dial unit delivers 0.01 ml containing 0.1 mg (100 mcg). A setting of 25 therefore delivers 0.25 ml containing 2.5 mg, while a setting of 50 delivers 0.5 ml containing 5 mg.
Pen settings apply to each individual administration. These calculations only apply to a concentration of 10 mg/ml and a device confirmed to deliver 0.01 ml per dial unit.